The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

The server encountered an error and could not complete your request. If the problem persists, please contact us using the ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Weight-loss drugs significantly improve health, though they’re also tied to increased spending on other medical care that’s ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lilly 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide.

A series of lawsuits have been filed in Marion County court alleging that drug manufacturer Eli Lilly downplayed the side ...

Shares of Eli Lilly & Co. suffered their biggest selloff in 26 years on Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations.